Detalhe da pesquisa
1.
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Cancer Immunol Immunother
; 67(8): 1251-1260, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29869168
2.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology
; 12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114242
3.
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.
Adv Sci (Weinh)
; 10(34): e2304818, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37863812
4.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience
; 25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072551
5.
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Cancer Immunol Res
; 10(4): 498-511, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362043
6.
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Clin Cancer Res
; 27(11): 3167-3177, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785484
7.
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Front Immunol
; 11: 614363, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488625